A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

NCT06859073 | Recruiting Phase 1 FDA Drug

• 2 other identifiers: NN4004-8071U1111-1317-9961
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 2

Brief Summary

This study will evaluate an investigational drug called NNC4004-0002. "Investigational" means NNC4004-0002 has not been approved for sale/ for clinical use or for the use described in this study/ by any regulatory authority. Its use in this study is experimental. This will be the first time that NNC4004-0002 will be given to human. This study will be testing the ability of the study medicine to lower serum uric acid. The main aim of this study will be to see if the new study medicine is safe and tolerated by the body after a single dose of study medicine in adults with asymptomatic hyperuricemia. Participants will either get NNC4004-0002 (the study medicine), or saline. Which treatment the participant get will be decided by chance. The participant will get the medicine as an injection under their skin. Depending on the dose they will receive, participant may need more than one injection. The study will last for about 19 months in total. The participant will take part in the study for about 7 months. Participant will have approximately 14 visits to the clinic and one of them will be a 4 night in-house stay.

Conditions

Healthy Volunteers; Hyperuricemia

Outcome Measures

Primary Outcomes (1)

• Number of Treatment-emergent adverse event (TEAEs)

  Count

  From dosing (day 1) until end of study (approximately 28 weeks)

Secondary Outcomes (5)

• AUC(0-72): The area under the NNC4004-0002 plasma concentration-time curve from time zero to the 72 hours after a single dose

  From dosing (day 1) to 72 hours postdose

• Cmax: The maximum concentration of NNC4004-0002 in plasma

  From dosing (day 1) to 72 hours postdose

• tmax: The time from dose administration to the maximum plasma concentration of NNC4004-0002

  From dosing (day 1) to 72 hours postdose

• Renal clearance

  From time of dose to 72 hours postdose

• Changes in serum Uric Acid (sUA) over time

  From baseline through the end of the study (approximately 28 weeks)

Study Arms (2)

NNC4004-0002

EXPERIMENTAL

Participants will receive a single dose of NNC4004-0002 injected subcutaneously. Trial will include up to 6 ascending single-dose cohorts.

Drug: NNC4004-0002

Placebo

PLACEBO COMPARATOR

Participants in each cohort will receive placebo matched to NNC4004-0002 injected subcutaneously.

Drug: Placebo

Interventions

NNC4004-0002 DRUG

NNC4004-0002 will be given as a single ascending dose via subcutaneous route.

NNC4004-0002

Placebo DRUG

Placebo matched to NNC4004-0002 will be given via subcutaneous route.

Placebo

Eligibility Criteria

• Age: 35 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males or females 35 to 75 years of age at the time of signing the informed consent form (ICF).
• Considered to be generally healthy based on medical history, physical examination, and the re-sults of vital signs, electrocardiogram, and clinical laboratory tests performed during the screening visit, as judged by the investigator.
• Body mass index (BMI) 20 to 35 kilogram per meter square (kg/m2) (both inclusive) at screening.
• Serum uric acid levels greater than or equal to (≥) 6.8 miligram per decileter (mg/dL) to less than or equal (≤) 12 mg/dL on 2 consecutive screening samples (the first at the screening visit \[V1\], and the second taken at V2 \[day -1\]; samples at least 7 days apart).

You may not qualify if:

• Female who is pregnant, breastfeeding, or intends to become pregnant or is of childbearing po-tential and not using an adequate contraceptive method.
• Male of reproductive age who, or whose female partner(s), is not using an adequate contraceptive method.
• Present or prior history of gout, or present or prior use of serum Uric acid (sUA) lowering medication.
• Serious cardiovascular or hepatic disease, current or past malignancies, or chronic debilitating neurologic, gastrointestinal, or inflammatory diseases.
• History or current diagnosis of chronic history kidney disease.
• Screening alanine transaminase (ALT) or aspartate aminotransferase (AST) values greater than (\>) 2 multiply by (×) upper limit normal (ULN) or total bilirubin \>1.5× ULN.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (2)

PAREXEL Glendale/LA EPCU

Glendale, California, 91206, United States

NOT YET RECRUITING

PAREXEL Intl - EPCU-Baltimore

Baltimore, Maryland, 21225, United States

RECRUITING

MeSH Terms

Conditions

Hyperuricemia

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Clinical Transparency (dept. 2834)

  Novo Nordisk A/S

  STUDY DIRECTOR

Central Study Contacts

Novo Nordisk

CONTACT

(+1) 866-867-7178; clinicaltrials@novonordisk.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 27, 2025
• First Posted: March 5, 2025
• Study Start: November 13, 2024
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: September 24, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will share

Locations

US (2)